12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Idelalisib: Additional Phase III data

Additional data from the double-blind, international Phase III Study 116 in 220 previously treated CLL patients showed that twice-daily 150 mg oral idelalisib plus rituximab led to a 24-week PFS rate of 93% vs. 46% for placebo plus rituximab (p<0.0001). In October, Study 116 was stopped early on the recommendation of an independent DMC after a predefined interim analysis at 50% of the planned total number of 119 events of CLL progression or death showed that idelalisib plus rituximab met the primary endpoint of improving median PFS vs. placebo plus rituximab (not yet reached vs. 5.5 months, p<0.0001)...

Read the full 468 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >